From the standpoint of diabetes health care providers and people with diabetes, the general availability of HbA 1c assays has been one of the most important advances in the past 20 years. HbA 1c has become the measurement around which knowledge about the relationship between glycaemic control and the risk of diabetic complications has been converted into an evidence base via the landmark DCCT Unfortunately, all of these aspirations for the use of an undoubtedly valuable measurement have been confounded by the wide diversity of analytical methods, reference ranges and reporting protocols for HbA 1c among UK laboratories. For example, a survey carried out in June 1999 among the 12 principal NHS Chemical Pathology Laboratories in Greater Manchester established that nine different HbA 1c methods were in use, giving rise to nine different reference ranges and six different reporting protocols. In many cases, the differences between the reference ranges and the target values in the reporting protocols were much greater than the differences that would imply clinical action. Furthermore, it is not at all clear that the changed management thresholds that have been derived from the DCCT and UKPDS (both used centralized, standardized assays) can be extrapolated to the values produced by all these alternative methodologies. In simple terms: does an HbA 1c change of 1% have the same therapeutic implication in all assays and how do assays relate to one another in respect of a target level for HbA 1c at which the risk of complications is minimized?
Some clinicians and patients, therefore, are faced with trying to reconcile results on the same person derived from different assays. Others are faced with the dif®culty of knowing how to extrapolate decision-making from the evidence (DCCT and UKPDS) to the results of an assay that has a completely different reference range. In the era of clinical service assessment such problems have additional dimensions. Thus, whereas it is dif®cult enough for individual clinical staff with individual patients to make management decisions over time, it becomes completely impossible to compare the clinical performance of one service with another if the HbA 1c data have been derived from assays with different characteristics. Nothing would be more guaranteed to discredit the current move towards accountability through clinical governance than the use of`performance indicators' that are not transparently related to the evidence base and are not robustly comparable.
Clinicians and patients will therefore bene®t by a change of all UK laboratories to`DCCTaligned' HbA 1c assays. This will have an enormously bene®cial impact on implementing evidence-based care, on the development of
